Developing cell based therapeutic products.

 

 

Cure Disease Like Never Before

Platforms

TriSafe Platform:

Proprietery Alternation on the Affinity of scFv to Reduce Non-Specificity.

 

TriSure Platform :

Integrated Proprietary Modulator to Change the Inhibitory Landscape of Tumor Micro-Environment.

 

TriExpan Platform:

Proprietary Co-Stimulator Factors to Increase the Persistence, Activation and Expansion of T cells.

 

TriGration Platform:

Proprietary Guider for Directional T Cell Migration and Killing.

 

FIT Platform:

Proprietary Fast-In-Transfer Technology for Efficient Gene Delivery and Immune Cell Manufacture.

 

Program: ARM011  

Non viral approach for blood malignancies   

Stage- Human Trial/IND.

 

Program:ARM022

 Unique Design CAR-T for Blood Malignancies.

Stage- Human Trial/IND.

 

Program:ARM003

Renovated CAR-T for Solid Tumors.

Stage- Human Trial/IND

 

Program:ARM004

Retro-COMBO for solid tumors  

Stage- Preclinical.

 

Program:ARM005

Dual Target CAR-T for Liquid Tumors   Stage- Preclinical/IND.

 

.

Pipelines